Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03523507
Other study ID # 898115
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date July 1, 2019
Est. completion date October 27, 2020

Study information

Verified date July 2019
Source Henry M. Jackson Foundation for the Advancement of Military Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to investigate the efficacy and tolerability of fMRI-targeted repetitive transcranial magnetic stimulation (rTMS) in the treatment of depressive symptoms in service members with a history of concussive traumatic brain injury (TBI). Up to ninety participants will be randomized to active or sham treatment. Participants randomized into the active group will receive 20 sessions of left-sided dorsolateral prefrontal cortex (DLFPC) high-frequency rTMS, followed by right-sided DLFPC low-frequency rTMS. The DLPFC treatment area will be identified by using individual subject-level resting state network estimation (Hacker et al., 2013). Participants randomized into the sham treatment group will receive 20 sham treatments designed to have similar sound and tactile sensation, without producing active treatment. Participants will also be asked to complete regular follow-up evaluations for up to a total of six follow-up sessions. Those who do not respond to the treatment will have the option to receive active treatment through this study regardless of group assignment to active or sham.


Description:

This study aims to investigate the efficacy and tolerability of individual connectome-targeted repetitive transcranial magnetic stimulation (ICT-rTMS) treatment to enhance the rehabilitation of service members with symptoms of depression and history of concussive traumatic brain injury (TBI). This will be a multi-site, double-blinded, sham-controlled, prospective, randomized interventional trial. Up to ninety participants will be block randomized to active (ICT-rTMS) or sham treatment. Participants will receive 20 sessions of ICT-rTMS over approximately 5 weeks. Resting-state functional magnetic resonance imaging (rsfMRI) and structural MRI will be obtained at baseline to allow for the calculation of connectome-targeted treatment coordinates and ensure the absence of structural abnormalities. The rsfMRI scan at baseline will also be used to establish the baseline for the secondary imaging outcome measures. Treatment sessions will consist of high-frequency left dorsolateral prefrontal cortex (DLPFC) stimulation for 4,000 pulses followed by low-frequency right DLPFC stimulation for 1,000 pulses for a total stimulation time of approximately one hour per session. This protocol was chosen based on a recent meta-analysis (Brunoni et al., 2017) indicating that amongst the various treatment protocols, priming the low frequency right hemisphere stimulation with a high frequency left hemisphere stimulation led to the greatest efficacy for treatment of Major Depressive Episodes. Additionally, the overwhelming majority of the literature in TMS for depression targets the stimulation to DLPFC and the FDA has approved repetitive transcranial magnetic stimulation (rTMS) to DLPFC for the treatment of medication-resistant major depressive disorder (MDD). The primary outcome will be change in depression severity from baseline to post-treatment. The primary analysis will be a comparison between the ICT-rTMS and sham groups. Secondary outcome measures utilized will include cognitive, quality of life, and emotional regulation measures, as well as imaging changes. Additional analyses will include durability of effects during the 6 months following treatment.


Recruitment information / eligibility

Status Terminated
Enrollment 10
Est. completion date October 27, 2020
Est. primary completion date October 27, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 64 Years
Eligibility Inclusion Criteria: 1. Age 18-64 2. Current or former US military service member 3. Eligible for care at DoD facilities 4. Able to provide written, informed consent in English 5. History of concussive TBI: 1. >6 months prior to consent 2. Documented previously in medical records and/or as confirmed by the TBI Screener 6. Must meet Criterion A of the DSM-5 criteria for Major Depressive Disorder as determined by a trained assessor 7. Baseline MADRS >10 Exclusion Criteria: 1. Elevated risk of seizures: 1. Prior history of unprovoked seizures other than within 24 hours of concussive TBI 2. Family history of seizures 3. History of TBI resulting in penetrating trauma based on the TBI Screener 4. Presence of intracranial tumor or intraparenchymal hemorrhage based on the structural MRI scan 5. Heavy alcohol consumption within 48 hours, prior to any treatment session 6. Receiving tricyclic antidepressants or neuroleptics at doses that lower seizure threshold 2. Contraindications to awake 3T MRI without contrast: 1. Ferromagnetic implants or metallic shrapnel 2. Severe claustrophobia 3. Unable to lie awake, supine, stationary, with reasonable comfort in the scanner for approximately 45 minutes 4. Markedly distorted functional brain anatomy such that rsfMRI targeting cannot be performed 3. History of severe or recent uncontrolled heart disease 4. Presence of a cardiac pacemaker or intracardiac lines 5. Implanted neurostimulators and medication pumps 6. Presence of rapidly progressive illnesses such as late stage cancer, neurodegenerative conditions, major organ failure, etc. 7. History of Bipolar Disorder, Schizophrenia Spectrum Disorders, or Moderate/Severe Substance Use Disorders, with the exception of nicotine use disorders 8. Increased risk of suicide as clinically evaluated 9. Current evidence of substance-induced mood disorder, active psychosis, and/or depression secondary to general medical illness (other than TBI) 10. Concomitant or previous history of receiving open-label TMS, other neurostimulatory treatment, or electroconvulsive therapy 11. Pregnancy a. Female participants of childbearing potential must agree to use an effective method of birth control during the course of the study, or to remain abstinent from sex, to ensure they do not become pregnant during the course of the study 12. Unilateral or bilateral upper extremity amputation or other condition precluding motor threshold calibration 13. Any considerations that, in the opinion of the investigator, may adversely affect patient safety, participation, or the scientific validity of the data being collected (e.g., planned hospitalization halfway through the initial treatment period, limited life expectancy, etc.)

Study Design


Intervention

Device:
Active: rTMS
Daily sessions will consist of 3000 left-sided excitatory pulses at 10 Hz (with 4-second trains and 26-second inter-train interval) followed by 1000 right-sided inhibitory pulses at 1 Hz (in a single train). The DLPFC treatment target will be determined using individualized resting-state network mapping.
Sham: rTMS
Daily sessions will consist of the same total number of sham pulses, designed to have similar sound and tactile sensation, without producing active stimulation.

Locations

Country Name City State
United States Walter Reed National Military Medical Center Bethesda Maryland
United States Fort Belvoir Community Hospital Fort Belvoir Virginia

Sponsors (2)

Lead Sponsor Collaborator
Henry M. Jackson Foundation for the Advancement of Military Medicine Center for Neuroscience and Regenerative Medicine (CNRM)

Country where clinical trial is conducted

United States, 

References & Publications (2)

Brunoni AR, Chaimani A, Moffa AH, Razza LB, Gattaz WF, Daskalakis ZJ, Carvalho AF. Repetitive Transcranial Magnetic Stimulation for the Acute Treatment of Major Depressive Episodes: A Systematic Review With Network Meta-analysis. JAMA Psychiatry. 2017 Feb 1;74(2):143-152. doi: 10.1001/jamapsychiatry.2016.3644. Review. Erratum in: JAMA Psychiatry. 2017 Apr 1;74(4):424. — View Citation

Hacker CD, Laumann TO, Szrama NP, Baldassarre A, Snyder AZ, Leuthardt EC, Corbetta M. Resting state network estimation in individual subjects. Neuroimage. 2013 Nov 15;82:616-633. doi: 10.1016/j.neuroimage.2013.05.108. Epub 2013 Jun 2. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Improvement in Depressive Symptoms Compare change in overall Montgomery-Asberg Depression Rating Scale (MADRS) scores between participants randomized to ICT-rTMS and those randomized to blinded sham stimulation. The overall score ranges from 0 to 60 with a higher overall score indicating more severe depression. Change between baseline, post-treatment (i.e., within 10 days of treatement completion), and 6-month follow-up
Secondary Changes in Cognitive Function Assess changes in cognitive function and emotion processing as measured by the Automated Neuropsychological Assessment Metric (ANAM). Change between baseline, post-treatment (i.e., within 10 days of treatement completion), and 6-month follow-up
Secondary Changes in TBI-related Symptoms Assess changes in TBI-related symptoms as reflected by the TBI-QOL. Change between baseline, post-treatment (i.e., within 10 days of treatement completion), and 6-month follow-up
Secondary Changes in PTSD-related Symptoms Assess changes in PTSD-related symptoms as reflected by the PTSD Checklist for DSM-5 (PCL-5). Change between baseline, post-treatment (i.e., within 10 days of treatement completion), and 6-month follow-up
Secondary Changes in Tinnitus-related Symptoms To assess changes in tinnitus-related symptoms as reflected by the Mini Tinnitus Questionnaire (Mini TQ-12). Change between baseline, post-treatment (i.e., within 10 days of treatement completion), and 6-month follow-up
Secondary Frequency of Adverse Effects Compare the frequency and severity of adverse effects between those randomized to ICT-rTMS and those randomized to blinded sham stimulation. Change between baseline, post-treatment (i.e., within 10 days of treatement completion), and 6-month follow-up
Secondary Changes in Psychotherapeutic Changes Compare the number, dose, and/or type of adjunctive treatments undertaken by those randomized to ICT-rTMS as compared to those randomized to blinded sham stimulation. Change between baseline, post-treatment (i.e., within 10 days of treatement completion), and 6-month follow-up
Secondary Changes in Resting-state fMRI Assess changes in resting-state functional connectivity using functional magnetic resonance imaging (fMRI). Change between baseline, post-treatment (i.e., within 10 days of treatement completion), and 6-month follow-up
See also
  Status Clinical Trial Phase
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT05503316 - The Roll of Balance Confidence in Gait Rehabilitation in Persons With a Lesion of the Central Nervous System N/A
Completed NCT04356963 - Adjunct VR Pain Management in Acute Brain Injury N/A
Completed NCT03418129 - Neuromodulatory Treatments for Pain Management in TBI N/A
Terminated NCT03698747 - Myelin Imaging in Concussed High School Football Players
Recruiting NCT05130658 - Study to Improve Ambulation in Individuals With TBI Using Virtual Reality -Based Treadmill Training N/A
Recruiting NCT04560946 - Personalized, Augmented Cognitive Training (PACT) for Service Members and Veterans With a History of TBI N/A
Completed NCT05160194 - Gaining Real-Life Skills Over the Web N/A
Recruiting NCT02059941 - Managing Severe Traumatic Brain Injury (TBI) Without Intracranial Pressure Monitoring (ICP) Monitoring Guidelines N/A
Recruiting NCT03940443 - Differences in Mortality and Morbidity in Patients Suffering a Time-critical Condition Between GEMS and HEMS
Recruiting NCT03937947 - Traumatic Brain Injury Associated Radiological DVT Incidence and Significance Study
Completed NCT04465019 - Exoskeleton Rehabilitation on TBI
Recruiting NCT04530955 - Transitioning to a Valve-Gated Intrathecal Drug Delivery System (IDDS) N/A
Recruiting NCT03899532 - Remote Ischemic Conditioning in Traumatic Brain Injury N/A
Suspended NCT04244058 - Changes in Glutamatergic Neurotransmission of Severe TBI Patients Early Phase 1
Completed NCT03307070 - Adapted Cognitive Behavioral Treatment for Depression in Patients With Moderate to Severe Traumatic Brain Injury N/A
Recruiting NCT04274777 - The Relationship Between Lipid Peroxidation Products From Traumatic Brain Injury and Secondary Coagulation Disorders
Withdrawn NCT05062148 - Fundamental and Applied Concussion Recovery Modality Research and Development: Applications for the Enhanced Recovery N/A
Withdrawn NCT04199130 - Cognitive Rehabilitation and Brain Activity of Attention-Control Impairment in TBI N/A
Withdrawn NCT03626727 - Evaluation of the Efficacy of Sodium Oxybate (Xyrem®) in Treatment of Post-traumatic Narcolepsy and Post-traumatic Hypersomnia Early Phase 1